• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Ascendis Pharma A/S

    8/13/25 12:49:42 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASND alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Ascendis Pharma AS

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    04351P101

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    04351P101


    1Names of Reporting Persons

    Capital International Investors
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,099,512.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    3,109,225.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,109,225.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.6 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Ascendis Pharma AS
    (b)Address of issuer's principal executive offices:

    TUBORG BOULEVARD 12, HELLERUP, Denmark
    Item 2. 
    (a)Name of person filing:

    Capital International Investors
    (b)Address or principal business office or, if none, residence:

    333 South Hope Street, 55th Fl, Los Angeles, CA 90071
    (c)Citizenship:

    N/A
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    04351P101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    3,109,225 ** **Capital International Investors ("CII") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CII's divisions of each of the investment management entities collectively provide investment management services under the name "Capital International Investors." CII is deemed to be the beneficial owner of 3,109,225 shares or 5.6% of the 55,754,437 shares believed to be outstanding. Shares reported include 3,109,225 Depository Receipts, which represent 3,109,225 Common Stock.
    (b)Percent of class:

    5.6  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    3,099,512

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    3,109,225

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Capital International Investors
     
    Signature:Jae Won Chung
    Name/Title:Vice President and Senior Counsel II, Capital Research and Management Company
    Date:08/12/2025
    Get the next $ASND alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASND

    DatePrice TargetRatingAnalyst
    1/28/2026$342.00Overweight
    Barclays
    11/18/2025$255.00Peer Perform
    Wolfe Research
    10/17/2025$271.00Strong Buy
    Raymond James
    7/3/2025$250.00Overweight
    Morgan Stanley
    5/5/2025$250.00Equal-Weight → Overweight
    Morgan Stanley
    4/16/2025$205.00Outperform
    RBC Capital Mkts
    1/7/2025$196.00Buy
    UBS
    9/5/2024$180.00Perform → Outperform
    Oppenheimer
    More analyst ratings

    $ASND
    SEC Filings

    View All

    SEC Form 6-K filed by Ascendis Pharma A/S

    6-K - Ascendis Pharma A/S (0001612042) (Filer)

    2/11/26 4:50:29 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 20-F filed by Ascendis Pharma A/S

    20-F - Ascendis Pharma A/S (0001612042) (Filer)

    2/11/26 4:15:33 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Ascendis Pharma A/S

    SCHEDULE 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    2/11/26 10:57:26 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results

    Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 millionQ4 2025 operating profit of €10 million and cash flow from operating activities of €73 millionTransCon® CNP under FDA Priority Review, PDUFA action goal date of February 28, 2026Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. "With a continued focus on making a meaningful difference for patients, we believe Ascendis is entering a steep growth phase as we transform into a leading global biopharma company,"

    2/11/26 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pendopharm Announces the Approval of Yorvipath® (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults

    MONTREAL, Feb. 6, 2026 /CNW/ - Pendopharm, a division of Pharmascience Inc., announced today that Health Canada has granted market authorization for Yorvipath® (palopegteriparatide injection), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of chronic hypoparathyroidism in adults. Yorvipath®, was developed by Ascendis Pharma A/S (NASDAQ:ASND) ("Ascendis"). This approval follows the exclusive distribution agreement signed in July 2024 between Pendopharm and Ascendis Pharma, under which Pendopharm is responsible for the regulatory approval and commerc

    2/6/26 3:19:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026

    COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on February 11, 2026, at 4:30 p.m. Eastern Time (ET) to discuss 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma

    2/4/26 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Ascendis Pharma with a new price target

    Barclays initiated coverage of Ascendis Pharma with a rating of Overweight and set a new price target of $342.00

    1/28/26 7:15:39 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Ascendis Pharma with a new price target

    Wolfe Research initiated coverage of Ascendis Pharma with a rating of Peer Perform and set a new price target of $255.00

    11/18/25 8:20:21 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on Ascendis Pharma with a new price target

    Raymond James initiated coverage of Ascendis Pharma with a rating of Strong Buy and set a new price target of $271.00

    10/17/25 8:28:03 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Financials

    Live finance-specific insights

    View All

    Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results

    Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 millionQ4 2025 operating profit of €10 million and cash flow from operating activities of €73 millionTransCon® CNP under FDA Priority Review, PDUFA action goal date of February 28, 2026Conference call today at 4:30 pm ET COPENHAGEN, Denmark, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. "With a continued focus on making a meaningful difference for patients, we believe Ascendis is entering a steep growth phase as we transform into a leading global biopharma company,"

    2/11/26 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026

    COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026, after the close of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on February 11, 2026, at 4:30 p.m. Eastern Time (ET) to discuss 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma

    2/4/26 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)

    – Once-weekly TransCon® CNP and TransCon® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks – Annualized growth velocity (AGV) exceeded the 97th-percentile of average stature children – ACH height Z-score improvements indicated a tripling of efficacy compared to TransCon CNP monotherapy – Combination therapy demonstrated benefits beyond linear growth with improvements in body proportionality and arm span, aligning with the increase in linear growth – All children completed 52 weeks of treatment and remain on therapy in COACH as of today – Combination therapy was generally well tolerated, with generally mild treatment-emergent adverse

    1/8/26 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Leadership Updates

    Live Leadership Updates

    View All

    Ascendant Resources Announces Results of Annual General Meeting of Shareholders

    TORONTO, ON / ACCESSWIRE / June 13, 2024 / Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting resultsof the Company's 2024 Annual General Shareholders' Meeting (the "Meeting") held on June 13, 2024, in Toronto, Ontario.A total of 51,497,589 common shares were voted at the Meeting, representing 27.59% of the votes attached to all outstanding common shares of the Company. All matterspresented for shareholder approval at the Meeting were duly authorized and approved as follows:Number of Directors to be ElectedOn a vote by a show of hands, the resolution to set the number of directors to be elected at the meeting at six (6) was approv

    6/13/24 5:55:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors

    COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital. Ascendis Pharma has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company. In addition, Ascendis will be eligible to receive development, regulatory, and sales milestone payments of up to

    1/29/24 8:30:00 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders

    TSX: ASNDwww.ascendantresources.com All matters overwhelmingly approved by shareholdersTORONTO, Aug. 23, 2023 /PRNewswire/ - Ascendant Resources Inc. (TSX:ASND) (OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting results of the Company's 2023 Annual and Special Shareholders' Meeting (the "Meeting") held on August 23, 2023, in Toronto, Ontario. A total of 43,635,681 common shares were voted at the Meeting, representing 32.98% of the votes attached to all outstanding common shares of the Company.  All matters presented for shareholder approval at the Me

    8/23/23 4:48:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 5:46:12 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 2:57:14 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 1:28:32 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care